Avance Biosciences now offers wet-lab analytical support for AI drug discovery teams, turning computational predictions into experimental data that can be validated and fed back into models. Backed by automated workflows, an API-connected LIMS and a GLP and cGMP-grade quality system, the service helps AI-first biotechs move from promising candidates to proven results.
Avance Biosciences™ is excited to announce that we will be exhibiting at the Society for Immunotherapy of Cancer's (SITC) 41st Annual Meeting, taking place November 4–8, 2026 at the Phoenix Convention Center in Phoenix, AZ. Visit us at Booth #528 during the Exhibit Hall to meet our team and [...]
Avance Biosciences will exhibit at Advanced Therapies USA 2026, highlighting cell and gene therapy characterization and release testing, viral vector testing, gene editing on/off-target analysis, and CMC-aligned testing support. Visit our team at Booth #511 to discuss analytical strategies for your cell and gene therapy program...
Avance Biosciences will exhibit at AAPS PharmSci 360 2026, highlighting bioanalytical method development and validation, immunogenicity (ADA) testing, biomarker and PK/PD testing, and potency and biologics characterization. Visit our team at Booth #1643 to discuss analytical strategies for your development program...
Avance Biosciences will exhibit at BioProcess International and Cell & Gene Therapy International 2026, highlighting analytical support for mRNA therapeutics and RNA vaccines, on/off-target analysis, biodistribution analysis, whole genome sequencing, and potency testing. Visit our team at Booth #1402 to discuss analytical strategies for advancing biologics and next-generation therapies...
The FDA has opened applications for a new Expedited IND Pilot that pairs drug sponsors with Qualified Research Institutions to speed up the path to first-in-human trials, with applications due October 30, 2026.
Avance Biosciences is hiring a Scientific Account Manager in Houston, TX — a great next step for PhD-level scientists ready to trade the bench for a client-facing role. Build relationships with biotech and pharma leaders, present our analytical and bioanalytical capabilities, and grow your career with hands-on mentorship and structured training. Apply today and help us connect great science with the people who need it...
Keeping up with new FDA guidance documents can be challenging. The FDA regularly publishes new draft and final guidance covering topics ranging from drug development and manufacturing to diagnostics, biologics, cell and gene therapy, medical devices, and regulatory policy...
GentiBio recently presented genome editing safety data during the “On- and Off-Target Method Development” session st the 2026 ASGCT Meeting, highlighting the extensive off-target characterization strategy used to support development of GNTI-122, an engineered regulatory T cell (Treg) therapy for type 1 diabetes (T1D). The presentation is particularly timely given the recent FDA [...]
Avance Biosciences will be exhibiting at the ASGCT Annual Meeting in Boston, May 11–15, 2026. Visit Booth #1062 to connect with our team and learn how our bioanalytical and CMC testing services support cell and gene therapy development[...]
Avance Biosciences is a leading Contract Research Organization (CRO) and Contract Testing Organization (CTO) providing CGMP and GLP-compliant analytical and bioanalytical services to support drug development. From early discovery through clinical development and commercialization, we provide CGMP and GLP-compliant services tailored to your therapeutic modality and regulatory needs.
